Nivolumab is a type of immunotherapy drug that is used to treat several types of cancer, including lung, kidney, and skin cancer. The company that manufactures nivolumab is Bristol-Myers Squibb (BMS) [1][3]. According to the company's website, nivolumab is marketed under the brand name Opdivo [2].

BMS has been granted approval by the US Food and Drug Administration (FDA) for the use of Opdivo (nivolumab) in the treatment of small cell lung cancer (SCLC) [3]. This approval was based on the results of a clinical trial which showed that Opdivo improved overall survival in patients with SCLC [3].

In summary, based on the available information, the global manufacturer of nivolumab is Bristol-Myers Squibb, and it is marketed under the brand name Opdivo.

Sources:
[1] <https://www.drugpatentwatch.com/p/biologics/ingredient/nivolumab>
[2] <https://www.opdivo.com/>
[3] <https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Small-Cell-Lung-Cancer-US-Indication/default.aspx>